Dianthus CAO sells 20K shares after option exercise

Dianthus Therapeutics’ chief accounting officer exercised 20,000 options and sold the resulting shares under a pre-arranged Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Dianthus Therapeutics, Inc. (DNTH) reported that its Chief Accounting Officer, Edward Carr, exercised options for 20,000 shares of common stock on September 17, 2026 at an exercise price of $17.88 per share and sold the same 20,000 shares in multiple market transactions on that date. The company reports that the options exercise and related sales were made under a Rule 10b5-1 trading plan adopted by Mr. Carr on June 18, 2026, and that he held 43,818 stock options after the exercise.

Insider Trade Summary 10b5-1

Exercise and Sale: 20,000 shares ($1.67M approx. pre-tax spread)

Exercise and Sale 7 txns

Insider CARR EDWARD

Role CHIEF ACCOUNTING OFFICER

Sold 20,000 shs ($2.03M)

Approx. gross sale proceeds $2.03M

Approx. exercise cost $358K

Approx. pre-tax spread $1.67M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F7	20,000	$0.00	$0.00
Exercise	Common Stock F1	20,000	$17.88	$358K
Sale	Common Stock F1, F2	7,928	$100.43	$796K
Sale	Common Stock F1, F3	6,771	$101.37	$686K
Sale	Common Stock F1, F4	3,501	$102.39	$358K
Sale	Common Stock F1, F5	1,100	$103.20	$114K
Sale	Common Stock F1, F6	700	$104.39	$73K

Holdings After Transaction: Stock Option (Right to Buy) — 43,818 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (7)

1. F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 18, 2026.
2. F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.98 to $100.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.99 to $101.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
4. F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $101.99 to $102.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
5. F5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.05 to $103.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
6. F6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $104.17 to $104.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
7. F7. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Key Figures

Options exercised: 20,000 shares Exercise price: $17.88 per share Shares sold: 20,000 shares +5 more

8 metrics

Options exercised 20,000 shares Stock options for Dianthus Therapeutics common stock exercised on September 17, 2026

Exercise price $17.88 per share Exercise price for 20,000 stock options converted into common stock

Shares sold 20,000 shares Common shares sold by Edward Carr on September 17, 2026

Weighted average sale price (lowest block) $100.43 per share Weighted average price for 7,928 shares sold within a $99.98–$100.97 range

Weighted average sale price (highest block) $104.39 per share Weighted average price for 700 shares sold within a $104.17–$104.63 range

Options held after exercise 43,818 options Stock options reported as held following the September 17, 2026 exercise

10b5-1 plan adoption date June 18, 2026 Date Edward Carr adopted the Rule 10b5-1 trading plan covering these transactions

Option expiration date January 23, 2034 Expiration date for the stock option award from which 20,000 options were exercised

Key Terms

Rule 10b5-1 trading plan, weighted average price, vest in equal monthly installments, continued service

4 terms

Rule 10b5-1 trading plan regulatory

"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported above is a weighted average price. The shares were sold"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

vest in equal monthly installments financial

"The shares of common stock underlying this stock option award vest in equal monthly installments"

continued service other

"subject to the Reporting Person's continued service to the Issuer on each such vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dianthus Therapeutics (DNTH) disclose about Edward Carr’s insider transactions?

Dianthus Therapeutics disclosed that Chief Accounting Officer Edward Carr exercised 20,000 stock options at $17.88 per share on September 17, 2026 and sold the resulting 20,000 common shares in multiple market transactions that same day.

How many DNTH shares did the chief accounting officer sell and at what prices?

Edward Carr sold a total of 20,000 shares of Dianthus Therapeutics common stock on September 17, 2026 at weighted average prices of $100.43, $101.37, $102.39, $103.20, and $104.39, each representing groups of trades within stated price ranges.

What options did the Dianthus Therapeutics CAO exercise in this Form 4?

He exercised 20,000 stock options for Dianthus Therapeutics common stock on September 17, 2026 at an exercise price of $17.88 per share. Following this exercise, the filing reports that he held 43,818 stock options from that award.

Were the DNTH insider transactions made under a Rule 10b5-1 plan?

Yes. A footnote states the reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Edward Carr on June 18, 2026, indicating the trades were pre-arranged under that plan.

How do the exercised DNTH options vest for Edward Carr?

A footnote explains that the common shares underlying this stock option award vest in equal monthly installments over four years after January 1, 2024, subject to Edward Carr’s continued service to Dianthus Therapeutics on each vesting date.

What price ranges applied to the DNTH share sales reported by the CAO?

The sales used weighted average prices. Footnotes state the underlying trades occurred in ranges of $99.98–$100.97, $100.99–$101.95, $101.99–$102.95, $103.05–$103.38, and $104.17–$104.63 per share, with detailed breakdowns available on request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 04:37 PM Accepted by SEC EDGAR 09/18/2026 - 04:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARR EDWARD

(Last) (First) (Middle)

C/O DIANTHUS THERAPEUTICS, INC.

7 TIMES SQUARE, 43RD FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dianthus Therapeutics, Inc. /DE/ [ DNTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF ACCOUNTING OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/17/2026		M(1)		20,000	A	$17.88	20,000	D
Common Stock	09/17/2026		S(1)		7,928	D	$100.43(2)	12,072	D
Common Stock	09/17/2026		S(1)		6,771	D	$101.37(3)	5,301	D
Common Stock	09/17/2026		S(1)		3,501	D	$102.39(4)	1,800	D
Common Stock	09/17/2026		S(1)		1,100	D	$103.2(5)	700	D
Common Stock	09/17/2026		S(1)		700	D	$104.39(6)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$17.88	09/17/2026		M(1)			20,000	(7)	01/23/2034	Common Stock	20,000	$0	43,818	D

Explanation of Responses:

1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 18, 2026.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.98 to $100.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.99 to $101.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $101.99 to $102.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

5. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.05 to $103.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

6. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $104.17 to $104.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

7. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Adam Veness, as attorney-in-fact for Edward Carr	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)